PMC:7033263 / 13896-14537 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T49","span":{"begin":268,"end":278},"obj":"Body_part"},{"id":"T50","span":{"begin":554,"end":561},"obj":"Body_part"},{"id":"T51","span":{"begin":602,"end":610},"obj":"Body_part"}],"attributes":[{"id":"A49","pred":"fma_id","subj":"T49","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A50","pred":"fma_id","subj":"T50","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T60","span":{"begin":39,"end":48},"obj":"Disease"},{"id":"T61","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"T62","span":{"begin":487,"end":506},"obj":"Disease"},{"id":"T63","span":{"begin":497,"end":506},"obj":"Disease"},{"id":"T64","span":{"begin":567,"end":575},"obj":"Disease"}],"attributes":[{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T95","span":{"begin":49,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T96","span":{"begin":260,"end":261},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T97","span":{"begin":374,"end":375},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T98","span":{"begin":382,"end":385},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T99","span":{"begin":518,"end":519},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T100","span":{"begin":565,"end":566},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T101","span":{"begin":585,"end":590},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":3,"end":12},"obj":"Chemical"},{"id":"T11","span":{"begin":125,"end":148},"obj":"Chemical"},{"id":"T12","span":{"begin":125,"end":134},"obj":"Chemical"},{"id":"T13","span":{"begin":139,"end":148},"obj":"Chemical"},{"id":"T14","span":{"begin":248,"end":258},"obj":"Chemical"},{"id":"T15","span":{"begin":268,"end":278},"obj":"Chemical"},{"id":"T16","span":{"begin":288,"end":295},"obj":"Chemical"},{"id":"T17","span":{"begin":446,"end":456},"obj":"Chemical"},{"id":"T18","span":{"begin":554,"end":561},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_50266"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T107","span":{"begin":0,"end":81},"obj":"Sentence"},{"id":"T108","span":{"begin":82,"end":220},"obj":"Sentence"},{"id":"T109","span":{"begin":221,"end":373},"obj":"Sentence"},{"id":"T110","span":{"begin":374,"end":507},"obj":"Sentence"},{"id":"T111","span":{"begin":508,"end":641},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"2_test","denotations":[{"id":"32078069-14985565-22841770","span":{"begin":212,"end":214},"obj":"14985565"},{"id":"32078069-29382391-22841771","span":{"begin":216,"end":218},"obj":"29382391"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"359","span":{"begin":171,"end":179},"obj":"Species"},{"id":"360","span":{"begin":202,"end":210},"obj":"Species"},{"id":"361","span":{"begin":460,"end":468},"obj":"Species"},{"id":"362","span":{"begin":538,"end":547},"obj":"Species"},{"id":"363","span":{"begin":567,"end":575},"obj":"Species"},{"id":"364","span":{"begin":585,"end":590},"obj":"Species"},{"id":"365","span":{"begin":125,"end":134},"obj":"Chemical"},{"id":"366","span":{"begin":139,"end":148},"obj":"Chemical"},{"id":"367","span":{"begin":248,"end":258},"obj":"Chemical"},{"id":"368","span":{"begin":446,"end":456},"obj":"Chemical"},{"id":"369","span":{"begin":27,"end":48},"obj":"Disease"},{"id":"370","span":{"begin":184,"end":201},"obj":"Disease"},{"id":"371","span":{"begin":487,"end":506},"obj":"Disease"}],"attributes":[{"id":"A359","pred":"tao:has_database_id","subj":"359","obj":"Tax:694009"},{"id":"A360","pred":"tao:has_database_id","subj":"360","obj":"Tax:9606"},{"id":"A361","pred":"tao:has_database_id","subj":"361","obj":"Tax:9606"},{"id":"A362","pred":"tao:has_database_id","subj":"362","obj":"Tax:2697049"},{"id":"A363","pred":"tao:has_database_id","subj":"363","obj":"Tax:694009"},{"id":"A364","pred":"tao:has_database_id","subj":"364","obj":"Tax:9606"},{"id":"A365","pred":"tao:has_database_id","subj":"365","obj":"MESH:D061466"},{"id":"A366","pred":"tao:has_database_id","subj":"366","obj":"MESH:D019438"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"MESH:C000606551"},{"id":"A368","pred":"tao:has_database_id","subj":"368","obj":"MESH:C000606551"},{"id":"A369","pred":"tao:has_database_id","subj":"369","obj":"MESH:D018352"},{"id":"A370","pred":"tao:has_database_id","subj":"370","obj":"MESH:D018352"},{"id":"A371","pred":"tao:has_database_id","subj":"371","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"No antiviral treatment for coronavirus infection has been proven to be effective. Previous studies showed the combination of lopinavir and ritonavir may be beneficial for SARS-CoV and MERS-CoV infected patients [31, 32]. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) showed significant improvement for the first case in US [24]. A trial has been initiated quickly to assess the efficacy and safety of remdesivir in patients hospitalized with 2019-nCoV infection. Recently, a potent binding of 2019-nCoV spike protein by a SARS-CoV specific human monoclonal antibody were under investigation [33]."}